James K. McCloskey, MD, John Theurer Cancer Center

Articles

Sequencing Therapies in Relapsed/Refractory ALL

August 24th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.

Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy

August 24th 2021

Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.

Approaches to Treatment for Relapsed/Refractory ALL

August 17th 2021

Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.

Approaches to Treatment After Failure to Achieve MRD Negativity

August 17th 2021

Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.

MRD Testing in ALL

August 10th 2021

An overview of the treatment implications of testing for minimal residual disease in pediatric and AYA patients with ALL.

Choosing a Treatment Setting for Patients With ALL

August 10th 2021

Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.

Approaches to Treatment of Ph- ALL

August 3rd 2021

Ibrahim Aldoss, MD; and James K. McCloskey, MD, discuss how to approach the treatment of a pediatric or AYA patient with ALL who is Philadelphia chromosome-negative (Ph-).

Treating Ph+ ALL: The GIMEMA Trial

August 3rd 2021

A review of the design, results, and practical implications of the GIMEMA Trial.

Approaches to Treatment of Ph+ ALL

July 27th 2021

A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).

Risk Assessment in ALL

July 27th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.